- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/605 - Glucagons
Détention brevets de la classe C07K 14/605
Brevets de cette classe: 1666
Historique des publications depuis 10 ans
|
85
|
96
|
78
|
110
|
115
|
107
|
129
|
123
|
146
|
149
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Novo Nordisk A/S | 2286 |
110 |
| Hanmi Pharm. Co., Ltd. | 581 |
84 |
| Zealand Pharma A/S | 262 |
82 |
| Eli Lilly and Company | 3926 |
81 |
| Sanofi | 4140 |
47 |
| Indiana University Research and Technology Corporation | 798 |
22 |
| Sun Pharmaceutical Industries Limited | 737 |
20 |
| MedImmune Limited | 630 |
19 |
| Merck Sharp & Dohme LLC | 3732 |
18 |
| Boehringer Ingelheim International GmbH | 4636 |
16 |
| Takeda Pharmaceutical Company Limited | 2721 |
16 |
| Hanmi Science Co., Ltd. | 133 |
16 |
| The Trustees of the University of Pennsylvania | 4390 |
15 |
| Intarcia Therapeutics, Inc. | 92 |
15 |
| The Scripps Research Institute | 1355 |
15 |
| I2o Therapeutics, Inc. | 30 |
15 |
| President and Fellows of Harvard College | 6043 |
14 |
| Hybio Pharmaceutical Co., Ltd. | 121 |
14 |
| Ip2ipo Innovations Limited | 175 |
14 |
| Amgen Inc. | 4256 |
12 |
| Autres propriétaires | 1021 |